

NOTICE OF CHANGE IN CORPORATE STRUCTURE
Pursuant to Section 4.9 of National Instrument 51-102
Continuous Disclosure Obligations

Item 1 Name of the Parties to the Transaction

Nirvana Life Sciences Inc. (“**Nirvana**”) (formerly Endocan Solutions Inc.) and 1253766 B.C. Ltd (“**1253BC**”)

Nirvana completed a reverse takeover transaction (“**RTO**”) with 1253BC (as further described below).

In connection with the RTO transaction, Endocan Solutions Inc. changed its name to “Nirvana Life Sciences Inc.” and is referred to below as the “**Resulting Issuer**”.

Item 2 Description of the Transaction

On June 4, 2021, the Company signed a share exchange agreement whereby the Company proposed to acquire 100% of the issued and outstanding shares of 1253766 B.C. Ltd. (formerly Nirvana Life Sciences Inc.) (“1253BC”) in exchange of approximately 39,000,000 common shares of the Company (the “Transaction”). Under the amendment signed on August 16, 2021, the Company would acquire 39,455,095 out of 39,827,095 issued and outstanding common shares in the capital of 1253BC. The Transaction is considered a reverse takeover transaction.

On January 10, 2022, three shareholders of 1253BC surrendered a total of 13,750,000 common shares of 1253BC for cancellation. As a result, the share exchange agreement was further amended to reflect the fact that the Company would acquire 25,905,095 common shares of 1253BC, which constitutes 99.34% of the issued and outstanding shares of 1253BC.

On March 17, 2022, the Company completed the acquisition transaction of 1253BC.

In connection with the RTO transaction, Endocan Solutions Inc. changed its name to “Nirvana Life Sciences Inc.”. The Resulting Issuer will continue the business which was previously conducted by 1253BC.

Item 3 Effective Date of Transaction

March 17, 2022

Item 4 Names of Each Party, if any, that Ceased to be an Issuer Subsequent to the Transaction and of each Continuing Entity

No entity ceased to be an issuer.

Continuing entities:

Nirvana Life Sciences Inc. (“Nirvana”) (formerly Endocan Solutions Inc.) with 1253BC as a subsidiary.

Item 5 Date of the Issuer’s First Financial Year-End Subsequent to the Transaction

The Resulting Issuer changed its year end from October 31 to April 30 as a result of the RTO with 1253BC (1253BC’s year end was April 30). April 30, 2022 will be the first year end subsequent to the RTO.

Item 6 Periods, including comparative periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Issuer’s First Financial Year Subsequent to the Transaction

Nirvana Life Sciences Inc. (formerly Endocan Solutions Inc.)

As a reporting issuer, for the period from closing the RTO and for its first financial year following the RTO, the Resulting Issuer will file:

- consolidated audited financial statements for the financial year ended April 30, 2022 compared to April 30, 2021
- consolidated unaudited interim financial statements for the 3 months ended July 31, 2022 compared to 3 months ended July 31, 2021
- consolidated unaudited interim financial statements for the 6 months ended October 31, 2022 compared to 6 months ended October 31, 2021
- consolidated unaudited interim financial statements for the 9 months ended January 31, 2023 compared to 9 months ended January 31, 2022

Item 7 Documents filed under NI 51-102 that described the Transaction

The terms of the RTO and Amalgamation are disclosed in:

- (a) Nirvana’s news release of June 4, 2021 announcing the proposed RTO;
- (b) Nirvana’s news releases of August 16, 2021 providing updates on the progress of the RTO;
- (c) Nirvana’s Filing Statement dated March 16, 2022 and filed on SEDAR on March 16, 2022;
- (d) the Resulting Issuer’s news release of March 14, 2022 (and related material change report filed on March 14, 2022) announcing the closing of the RTO,

copies of which have been filed on SEDAR and are available under the Resulting Issuer’s profile at www.sedar.com.

Item 8 Date of Report

June 13, 2022